These data demonstrate that XO promotes the expression of the proinflammatory cytokines IL1beta and IL18 in the mucosa of IBD patients by acting at transcriptional, and post-transcriptional level via NLRP3 inflammasome activation. The gene discussed is IL1B; the disease is inflammatory bowel disease.